Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The PREDICT Registry:
NCT03448926 · View on ClinicalTrials.gov ↗
Study Summary
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.
Conditions Studied
Interventions
- OTHER Treatment Recommendation Surveys
- DEVICE 7-gene biosignature
Study Locations (15)
Ohio
- Cleveland Clinic Akron General — Akron
- Cleveland Clinic Foundation Taussig Cancer Institute — Cleveland
- The Ohio State University — Columbus
California
- Sutter Institute for Medical Research — Sacramento
- Mills-Peninsula Medical Center — San Mateo
Colorado
- University of Colorado Denver — Aurora
- UC Health - Memorial Hospital, Colorado Springs — Colorado Springs
Massachusetts
- Dana-Farber Cancer Institute — Boston
- Dana-Farber/Brigham and Women's Cancer Center at South Shore — South Weymouth
Arizona
- Arizona Center for Cancer Care — Phoenix
Florida
- St. Joseph's Hospital Tampa — Tampa
Michigan
- Comprehensive Breast Care — Troy
New York
- Maimonides Cancer Center — Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2035-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03448926
The ClinicalTrials.gov registry entry for NCT03448926 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PreludeDx, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with DCIS appearing as the primary indexed condition, and to 2 interventions — of which Treatment Recommendation Surveys is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03448926 reports 15 study locations spanning 10 distinct geographic areas — top geographies include Ohio, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03448926 about?
NCT03448926 is a clinical study titled "The PREDICT Registry:". This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed...
What is the current status of trial NCT03448926?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2018-02-27. Estimated completion is 2035-12.
What conditions does trial NCT03448926 study?
This clinical trial studies the following conditions: DCIS. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03448926?
The interventions under investigation include: Treatment Recommendation Surveys (OTHER), 7-gene biosignature (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03448926?
This trial is sponsored by PreludeDx, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03448926 being conducted?
This trial has 15 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.